{
  "abstract": "Introduction Tedizolid is a promising alternative to linezolid for bone and joint infections (BJIs), but real-world comparative data remain scarce. We aimed to assess the effectiveness and hematological safety of tedizolid versus linezolid in this setting. Methods We conducted a retrospective, single-center observational study at Nimes University Hospital, a French BJIs reference center, including adults treated with linezolid or tedizolid for BJI between December 2018 and September 2023. The primary endpoint was a composite of clinical failure at end of treatment, relapse within 60 days, all-cause 1-year mortality, or antibiotic discontinuation due to adverse events. Secondary endpoints included each component separately and hematological trajectories. Inverse probability of treatment weighting was applied to adjust for confounders. Results A total of 202 patients were analyzed (147 linezolid; 55 tedizolid, including 38 switched from linezolid). Staphylococcus spp. accounted for 71% of cases, and 50.5% of infections were polymicrobial. The composite endpoint occurred in 38% of patients on linezolid and 22% on tedizolid (p = 0.04). In propensity-weighted analysis, tedizolid was non-inferior to linezolid (risk difference – 5.6%, 95% CI – 24.2–13.0%). Hematological tolerance favored tedizolid: adjusted hemoglobin and platelet count variations were significantly higher at day 28 (Δ hemoglobin + 1.09 g/dL, 0.54–1.65; p < 0.001; Δ platelets + 134.1 G/L, 92.0–176.3; p < 0.001). Conclusions Tedizolid was non-inferior to linezolid for the treatment of BJIs and was associated with improved hematological safety. These findings support the use of tedizolid as a valuable alternative in complex BJIs, particularly in patients at risk of cytopenia.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "name": "Charlène Aïn"
    },
    {
      "name": "Paul Laffont-Lozes"
    },
    {
      "name": "Albert Sotto"
    },
    {
      "name": "Julien Mazet"
    },
    {
      "name": "Aurélie Martin"
    },
    {
      "name": "Adeline Dubois"
    },
    {
      "name": "Nicolas Cellier"
    },
    {
      "name": "Paul Loubet"
    },
    {
      "name": "Romaric Larcher"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/1q25cbz05ab2r.bib",
  "cited_by": 0,
  "doi": "10.1007/s40121-026-01457-7",
  "fulltext_url": null,
  "id": "1q25cbz05ab2r",
  "issns": [
    "2193-8229",
    "2193-6382"
  ],
  "landing_url": "https://hal.science/hal-05841721v1",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "openalex",
      "2746|Orthopedic Infections and Treatments"
    ]
  ],
  "openalex": "W7223927426",
  "pdf_url": "https://hal.science/hal-05841721/document",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-27",
  "publisher": "Springer Verlag",
  "ris": "https://research.draconitic.com/paper/1q25cbz05ab2r.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:18:02Z",
      "native_id": "hal-05841721",
      "source": "hal",
      "url": "https://hal.science/hal-05841721v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2746|Orthopedic Infections and Treatments",
      "subfield": "surgery"
    }
  ],
  "title": "Comparative Effectiveness and Hematological Safety of Linezolid and Tedizolid in Bone and Joint Infections: A Retrospective Cohort Study",
  "title_text": "Comparative Effectiveness and Hematological Safety of Linezolid and Tedizolid in Bone and Joint Infections: A Retrospective Cohort Study",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:18:02Z",
  "url": "https://research.draconitic.com/paper/1q25cbz05ab2r",
  "venue": "Infectious Diseases and Therapy",
  "versions": []
}